OmniGuide's flexible laser tech:
This article was originally published in Clinica
OmniGuide has CE-marked for sale in Europe its flexible CO2 laser fibres for use in minimally-invasive surgery. Its OtoBeam and BeamPath systems, which are already approved in the US, can now be sold in all countries that accept the CE-mark, said the Cambridge, Massachusetts firm. Most CO2 lasers have a rigid articulating arm that limits the surgeon to procedures where a "line-of-sight" from outside the patient's body is possible, the firm claimed. The OmniGuide fibre, which is fitted to this existing base of CO2 laser systems, allows physicians to place the fibre into the patient's body under endoscopic guidance to treat lesions within the skull base, airway and larynx.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.